Literature DB >> 10550269

Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study.

S S Shoab1, J H Scurr, P D Coleridge-Smith.   

Abstract

AIM: to study the effect on plasma vascular endothelial growth factor (VEGF) levels of oral purified flavonoid fraction treatment for sixty days in patients with chronic venous disease (CVD).
MATERIAL AND METHODS: twenty patients <<CEAP>> (clinical stage 2-4) with chronic venous disease were included. Duplex ultrasonography was used to assess the venous disease. Patients were treated for 60 days with Daflon(R) 500 mg twice daily. Blood was collected from a foot vein immediately before starting treatment and within one week of stopping treatment. Plasma VEGF levels were determined using a sandwich ELISA method.
RESULTS: VEGF levels decreased in patients with stage C4 CVD after treatment with purified micronised flavonoid fraction treatment (98 pg/ml to 57 pg/ml). The levels of VEGF in patients with skin changes were significantly higher (98 pg/ml) than those with normal skin (9 pg/ml p=<0.001 Wilcoxon).
CONCLUSIONS: plasma VEGF levels were much higher in patients who have skin changes of CVD. Plasma VEGF protein decreases in patients with CVD-induced dermatologic changes following treatment with purified micronised flavonoid fraction. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550269     DOI: 10.1053/ejvs.1999.0890

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  9 in total

Review 1.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration.

Authors:  Raffaele Serra; Raffaele Grande; Lucia Butrico; Gianluca Buffone; Francesco G Caliò; Aida Squillace; Barbara A Rizzo; Mafalda Massara; Francesco Spinelli; Alessia G Ferrarese; Giovanni de Caridi; Luca Gallelli; Stefano de Franciscis
Journal:  Int Wound J       Date:  2014-02-25       Impact factor: 3.315

3.  Serum concentration of matrix metalloproteinases and angiogenic factors in patients with venous leg ulcers.

Authors:  Paweł Kolano; Igor A Bednarski; Marzena Kraska-Gacka; Joanna Narbutt; Aleksandra Lesiak
Journal:  Postepy Dermatol Alergol       Date:  2021-05-22       Impact factor: 1.837

4.  Varicose veins: role of mechanotransduction of venous hypertension.

Authors:  Hussein M Atta
Journal:  Int J Vasc Med       Date:  2012-02-12

Review 5.  Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.

Authors:  Armando Mansilha; Joel Sousa
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

6.  Diosmin Alleviates Venous Injury and Muscle Damage in a Mouse Model of Iliac Vein Stenosis.

Authors:  Zhiye Guo; Xiaolong Du; Yihua Zhang; Chunwan Su; Feng Ran; Qiulun Lu
Journal:  Front Cardiovasc Med       Date:  2022-01-13

Review 7.  Challenges in Healing Wound: Role of Complementary and Alternative Medicine.

Authors:  Prakash Monika; Mathikere Naganna Chandraprabha; Annapoorni Rangarajan; P Veena Waiker; Kotamballi N Chidambara Murthy
Journal:  Front Nutr       Date:  2022-01-20

8.  Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.

Authors:  Marcin Feldo; Magdalena Wójciak-Kosior; Ireneusz Sowa; Janusz Kocki; Jacek Bogucki; Tomasz Zubilewicz; Jan Kęsik; Anna Bogucka-Kocka
Journal:  Molecules       Date:  2019-09-12       Impact factor: 4.411

9.  Overexpression of cathepsin K and vascular endothelial growth factor in chronic venous ulcerations.

Authors:  Paweł Kolano; Igor A Bednarski; Aleksandra Lesiak; Małgorzata Skibińska; Olga Stasikowska-Kanicka; Marian Danilewicz; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.